Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France

IMPORTANCE: Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incidence has not been evaluated. OBJECTIVE: To describe the temporal evolutio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Neurol
Main Authors: Vukusic, Sandra, Rollot, Fabien, Casey, Romain, Pique, Julie, Marignier, Romain, Mathey, Guillaume, Edan, Gilles, Brassat, David, Ruet, Aurélie, De Sèze, Jérôme, Maillart, Elisabeth, Zéphir, Hélène, Labauge, Pierre, Derache, Nathalie, Lebrun-Frenay, Christine, Moreau, Thibault, Wiertlewski, Sandrine, Berger, Eric, Moisset, Xavier, Rico-Lamy, Audrey, Stankoff, Bruno, Bensa, Caroline, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Vaillant, Mathieu, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean-Philippe, Tourbah, Ayman, Guennoc, Anne-Marie, Hankiewicz, Karolina, Patry, Ivania, Nifle, Chantal, Maubeuge, Nicolas, Labeyrie, Céline, Vermersch, Patrick, Laplaud, David-Axel
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6724170/
https://ncbi.nlm.nih.gov/pubmed/31479149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.2670
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados